Compare OII & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | OGN |
|---|---|---|
| Founded | 1964 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | 1994 | 2020 |
| Metric | OII | OGN |
|---|---|---|
| Price | $40.94 | $13.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $41.00 | $10.33 |
| AVG Volume (30 Days) | 958.8K | ★ 2.2M |
| Earning Date | 10-21-2026 | 11-13-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 142.36 | N/A |
| EPS | 1.53 | ★ 1.56 |
| Revenue | $2,784,156,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $5.62 | N/A |
| Revenue Next Year | $3.59 | $2.07 |
| P/E Ratio | $27.14 | ★ $14.52 |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $22.13 | $5.69 |
| 52 Week High | $54.25 | $13.83 |
| Indicator | OII | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 64.80 |
| Support Level | $34.69 | $13.72 |
| Resistance Level | $53.64 | $13.83 |
| Average True Range (ATR) | 1.85 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 54.55 | 86.96 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.